ClinicalTrials.gg
Sign In
Not yet recruitingNCT06029478Updated Sep 8, 2023

Understanding Engagement Trends in Chondrosarcoma Clinical Trials

An observational study in Chondrosarcoma, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This study will admit a wide range of data on the clinical trial experience of chondrosarcoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chondrosarcoma patients.

02

Conditions studied

  • Chondrosarcoma

Browse trials for

Keywords

  • chondrosarcoma
03

In context

Chondrosarcoma

79 studies on the registry are indexed under Chondrosarcoma; 21 are open to participants now.

This study's planned enrollment of 500 is above the median of 86 across 18 observational studies indexed under Chondrosarcoma.

Browse Chondrosarcoma studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 111 studies on the registry; 109 are open to participants now.

Browse Power Life Sciences Inc. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with chondrosarcoma who are actively considering enrolling in a clinical trial for said condition, but have not yet completed enrollment and randomization.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years old
  • Able to comprehend the investigational nature of the protocol and provide informed consent
  • Diagnosis of chondrosarcoma

Exclusion criteria

Exclusion Criteria:

  • No diagnosis of chondrosarcoma confirmed
  • Inability to perform regular electronic reporting
  • Patient does not understand, sign, and return consent form
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of chondrosarcoma patients who decide to enroll in a clinical trial

    Time frame: 3 months

  2. Rate of chondrosarcoma patients who remain in clinical trial to trial completion

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Speetjens FM, de Jong Y, Gelderblom H, Bovee JV. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300. PubMed 27166664 ↗
  • Beena D, Kattoor J, Mathews A, P Nair S, M V, T P, N G. Mesenchymal Chondrosarcoma-A Retrospective study. Gulf J Oncolog. 2021 Jan;1(35):54-58. PubMed 33716213 ↗
  • Thompson LD, Gannon FH. Chondrosarcoma of the larynx: a clinicopathologic study of 111 cases with a review of the literature. Am J Surg Pathol. 2002 Jul;26(7):836-51. doi: 10.1097/00000478-200207000-00002. PubMed 12131151 ↗

Study documents

  • Informed consent form · Sep 1, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 8, 2023
StartEst.
Oct 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2026
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029478
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Oct 2024 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 8, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
415-900-4227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Chondrosarcoma →

Other studies from this sponsor

Power Life Sciences Inc. →

Start the discussion